Neurocrine Biosciences | NBIX - Loan Capital


Neurocrine Biosciences reported $169.5M in Loan Capital for its fiscal quarter ending in March of 2023.





Loan Capital Change Date
AbbVie USD 58.94B 4.03B Dec/2025
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 1.48B 1.2B Mar/2026
Alnylam Pharmaceuticals USD 2.48B 931K Mar/2026
Amgen USD 51.89B 1.88B Mar/2026
Biogen USD 6.29B 1.7M Mar/2026
BioMarin Pharmaceutical USD 1.43B 833.11M Mar/2026
Cytokinetics USD 247.21M 868.77M Mar/2026
Enanta Pharmaceuticals USD 0 0 Dec/2024
Gilead Sciences USD 20.86B 1.27B Mar/2026
Halozyme Therapeutics USD 1.94B 206.73M Mar/2026
Incyte USD 29.41M 785K Mar/2026
Ionis Pharmaceuticals USD 1.91B 9M Mar/2026
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pfizer USD 60.57B 1.08B Mar/2026
Prothena USD 0 0 Dec/2024
Regeneron Pharmaceuticals USD 1.99B 719.7M Mar/2026
Repligen USD 546.58M 4.37M Mar/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
Sarepta Therapeutics USD 838.16M 9.19M Mar/2026
Teva Pharmaceutical Industries USD 14.02B 971M Mar/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025
Xoma USD 94.38M 7.82M Sep/2025